Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 [phentermine/topiramate] to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 [phentermine/topiramate] to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Phentermine/topiramate (Primary) ; Phentermine; Topiramate
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms EQUATE
  • Sponsors VIVUS

    • Most Recent Events

    • 17 Oct 2013 Primary endpoint 'Greater-than-5%-reduction-of-bodyweight' has been met.
    • 05 Oct 2012 Results reporting cardiovascular outcomes presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 May 2010 The New Drug Application has been accepted by the FDA, with an action date of 28 October 2010.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top